Alumis and ACELYRIN are merging to create a strong biopharma company focused on immune diseases

From GlobeNewswire: 2025-04-04 16:34:00

Alumis Inc. and ACELYRIN, INC. have filed a joint proxy statement/prospectus for their proposed merger, creating a late-stage clinical biopharma company focused on immune-mediated diseases. Stockholders are set to benefit from a differentiated portfolio and strong financial position. Boards unanimously recommend voting “FOR” the merger, with a transaction completion expected in the second quarter of 2025. The merger will result in Alumis stockholders owning approximately 55% and ACELYRIN stockholders owning approximately 45% of the combined company. Key milestones include Phase 3 trial data for ESK-001 and Phase 2b LUMUS trial data in 2026. Pro forma cash of $737 million provides runway into 2027.

The transaction is subject to stockholder approval and other customary closing conditions, with Alumis and ACELYRIN holding respective Special Meetings of Stockholders in May. The combined company will have a strong leadership team and resources to maximize the value of its pipeline. For more information on the merger and voting process, Alumis and ACELYRIN stockholders can contact the respective proxy solicitors. The merger is expected to close in the second quarter of 2025, pending approval.



Read more at GlobeNewswire: Alumis and ACELYRIN File Joint Definitive Proxy Statement